Plasma kallistatin is associated with adiposity and cardiometabolic risk in apparently healthy African American adolescents

Haidong Zhu, Julie Chao, Ishita Kotak, Dehuang Guo, Samip J. Parikh, Jigar Bhagatwala, Yutong Dong, Sagar Y. Patel, Christopher P. Houk, Lee Chao, Yanbin Dong

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: It is generally recognized that obesity and cardiometabolic risk are more prevalent in African Americans. Kallistatin, a novel tissue kallikrein inhibitor, has anti-inflammatory and anti-oxidant properties. Thus, the goal of this study was to examine the relationships among plasma kallistatin levels, adiposity and cardiometabolic risk factors in African American adolescents. Materials/Methods: Plasma kallistatin levels were determined in 318 apparently healthy African American adolescents (aged 14-19 years, 48.1% females) by enzyme-linked immunosorbent assay. Results: Plasma kallistatin levels did not differ between males (27.9 ± 11.2 μg/mL) and females (26.8 ± 11.0 μg/mL) (p = 0.47). Plasma kallistatin levels were inversely correlated with percent body fat (% BF, r = - 0.13, p = 0.04), total cholesterol (r = - 0.28, p < 0.01), low density lipoprotein cholesterol (LDL, r = - 0.30, p < 0.01) and interleukin-6 (r = - 0.14, p = 0.05), but positively correlated with adiponectin (r = 0.16, p = 0.03) and high density lipoprotein (HDL, r = 0.17, p = 0.02). These correlations remained significant after adjustment for age, sex and body mass index percentiles. Stepwise multiple linear regression analysis showed that LDL cholesterol alone explained 14.2% of the variance in kallistatin, while % BF and adiponectin explained an additional 3.6% and 2.8% of the variance, respectively. Conclusions: The present study demonstrates that plasma kallistatin levels are inversely associated with adiposity, adverse lipid profiles and inflammation in apparently healthy African American adolescents. As a potent antioxidant and anti-inflammation agent, kallistatin may also hold therapeutic promise in cardiometabolic disorders.

Original languageEnglish (US)
Pages (from-to)642-646
Number of pages5
JournalMetabolism: Clinical and Experimental
Volume62
Issue number5
DOIs
StatePublished - May 1 2013

Fingerprint

Adiposity
African Americans
Adiponectin
LDL Cholesterol
Inflammation
Tissue Kallikreins
kallistatin
HDL Lipoproteins
Oxidants
Adipose Tissue
Linear Models
Interleukin-6
Body Mass Index
Anti-Inflammatory Agents
Obesity
Antioxidants
Enzyme-Linked Immunosorbent Assay
Cholesterol
Regression Analysis
Lipids

Keywords

  • Inflammation
  • Lipids
  • Obesity

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Plasma kallistatin is associated with adiposity and cardiometabolic risk in apparently healthy African American adolescents. / Zhu, Haidong; Chao, Julie; Kotak, Ishita; Guo, Dehuang; Parikh, Samip J.; Bhagatwala, Jigar; Dong, Yutong; Patel, Sagar Y.; Houk, Christopher P.; Chao, Lee; Dong, Yanbin.

In: Metabolism: Clinical and Experimental, Vol. 62, No. 5, 01.05.2013, p. 642-646.

Research output: Contribution to journalArticle

Zhu, Haidong ; Chao, Julie ; Kotak, Ishita ; Guo, Dehuang ; Parikh, Samip J. ; Bhagatwala, Jigar ; Dong, Yutong ; Patel, Sagar Y. ; Houk, Christopher P. ; Chao, Lee ; Dong, Yanbin. / Plasma kallistatin is associated with adiposity and cardiometabolic risk in apparently healthy African American adolescents. In: Metabolism: Clinical and Experimental. 2013 ; Vol. 62, No. 5. pp. 642-646.
@article{6cb3ea6a2239451f8edd39dc80069d28,
title = "Plasma kallistatin is associated with adiposity and cardiometabolic risk in apparently healthy African American adolescents",
abstract = "Objective: It is generally recognized that obesity and cardiometabolic risk are more prevalent in African Americans. Kallistatin, a novel tissue kallikrein inhibitor, has anti-inflammatory and anti-oxidant properties. Thus, the goal of this study was to examine the relationships among plasma kallistatin levels, adiposity and cardiometabolic risk factors in African American adolescents. Materials/Methods: Plasma kallistatin levels were determined in 318 apparently healthy African American adolescents (aged 14-19 years, 48.1{\%} females) by enzyme-linked immunosorbent assay. Results: Plasma kallistatin levels did not differ between males (27.9 ± 11.2 μg/mL) and females (26.8 ± 11.0 μg/mL) (p = 0.47). Plasma kallistatin levels were inversely correlated with percent body fat ({\%} BF, r = - 0.13, p = 0.04), total cholesterol (r = - 0.28, p < 0.01), low density lipoprotein cholesterol (LDL, r = - 0.30, p < 0.01) and interleukin-6 (r = - 0.14, p = 0.05), but positively correlated with adiponectin (r = 0.16, p = 0.03) and high density lipoprotein (HDL, r = 0.17, p = 0.02). These correlations remained significant after adjustment for age, sex and body mass index percentiles. Stepwise multiple linear regression analysis showed that LDL cholesterol alone explained 14.2{\%} of the variance in kallistatin, while {\%} BF and adiponectin explained an additional 3.6{\%} and 2.8{\%} of the variance, respectively. Conclusions: The present study demonstrates that plasma kallistatin levels are inversely associated with adiposity, adverse lipid profiles and inflammation in apparently healthy African American adolescents. As a potent antioxidant and anti-inflammation agent, kallistatin may also hold therapeutic promise in cardiometabolic disorders.",
keywords = "Inflammation, Lipids, Obesity",
author = "Haidong Zhu and Julie Chao and Ishita Kotak and Dehuang Guo and Parikh, {Samip J.} and Jigar Bhagatwala and Yutong Dong and Patel, {Sagar Y.} and Houk, {Christopher P.} and Lee Chao and Yanbin Dong",
year = "2013",
month = "5",
day = "1",
doi = "10.1016/j.metabol.2012.10.012",
language = "English (US)",
volume = "62",
pages = "642--646",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Plasma kallistatin is associated with adiposity and cardiometabolic risk in apparently healthy African American adolescents

AU - Zhu, Haidong

AU - Chao, Julie

AU - Kotak, Ishita

AU - Guo, Dehuang

AU - Parikh, Samip J.

AU - Bhagatwala, Jigar

AU - Dong, Yutong

AU - Patel, Sagar Y.

AU - Houk, Christopher P.

AU - Chao, Lee

AU - Dong, Yanbin

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Objective: It is generally recognized that obesity and cardiometabolic risk are more prevalent in African Americans. Kallistatin, a novel tissue kallikrein inhibitor, has anti-inflammatory and anti-oxidant properties. Thus, the goal of this study was to examine the relationships among plasma kallistatin levels, adiposity and cardiometabolic risk factors in African American adolescents. Materials/Methods: Plasma kallistatin levels were determined in 318 apparently healthy African American adolescents (aged 14-19 years, 48.1% females) by enzyme-linked immunosorbent assay. Results: Plasma kallistatin levels did not differ between males (27.9 ± 11.2 μg/mL) and females (26.8 ± 11.0 μg/mL) (p = 0.47). Plasma kallistatin levels were inversely correlated with percent body fat (% BF, r = - 0.13, p = 0.04), total cholesterol (r = - 0.28, p < 0.01), low density lipoprotein cholesterol (LDL, r = - 0.30, p < 0.01) and interleukin-6 (r = - 0.14, p = 0.05), but positively correlated with adiponectin (r = 0.16, p = 0.03) and high density lipoprotein (HDL, r = 0.17, p = 0.02). These correlations remained significant after adjustment for age, sex and body mass index percentiles. Stepwise multiple linear regression analysis showed that LDL cholesterol alone explained 14.2% of the variance in kallistatin, while % BF and adiponectin explained an additional 3.6% and 2.8% of the variance, respectively. Conclusions: The present study demonstrates that plasma kallistatin levels are inversely associated with adiposity, adverse lipid profiles and inflammation in apparently healthy African American adolescents. As a potent antioxidant and anti-inflammation agent, kallistatin may also hold therapeutic promise in cardiometabolic disorders.

AB - Objective: It is generally recognized that obesity and cardiometabolic risk are more prevalent in African Americans. Kallistatin, a novel tissue kallikrein inhibitor, has anti-inflammatory and anti-oxidant properties. Thus, the goal of this study was to examine the relationships among plasma kallistatin levels, adiposity and cardiometabolic risk factors in African American adolescents. Materials/Methods: Plasma kallistatin levels were determined in 318 apparently healthy African American adolescents (aged 14-19 years, 48.1% females) by enzyme-linked immunosorbent assay. Results: Plasma kallistatin levels did not differ between males (27.9 ± 11.2 μg/mL) and females (26.8 ± 11.0 μg/mL) (p = 0.47). Plasma kallistatin levels were inversely correlated with percent body fat (% BF, r = - 0.13, p = 0.04), total cholesterol (r = - 0.28, p < 0.01), low density lipoprotein cholesterol (LDL, r = - 0.30, p < 0.01) and interleukin-6 (r = - 0.14, p = 0.05), but positively correlated with adiponectin (r = 0.16, p = 0.03) and high density lipoprotein (HDL, r = 0.17, p = 0.02). These correlations remained significant after adjustment for age, sex and body mass index percentiles. Stepwise multiple linear regression analysis showed that LDL cholesterol alone explained 14.2% of the variance in kallistatin, while % BF and adiponectin explained an additional 3.6% and 2.8% of the variance, respectively. Conclusions: The present study demonstrates that plasma kallistatin levels are inversely associated with adiposity, adverse lipid profiles and inflammation in apparently healthy African American adolescents. As a potent antioxidant and anti-inflammation agent, kallistatin may also hold therapeutic promise in cardiometabolic disorders.

KW - Inflammation

KW - Lipids

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=84876693425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876693425&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2012.10.012

DO - 10.1016/j.metabol.2012.10.012

M3 - Article

C2 - 23190873

AN - SCOPUS:84876693425

VL - 62

SP - 642

EP - 646

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 5

ER -